Pregabalin In Partial Seizures Extension Study

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.227 enrolled

Overview

To evaluate long-term efficacy and safety of pregabalin (150 to 600mg/day) as adjunctive treatment in patients with partial seizures.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

227

Conditions

Seizures

Interventions

PregabalinDRUG

Pregabalin

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * met the inclusion/exclusion criteria for A0081005 * have completed the 21-week study and have shown a significant clinical response and wish to continue treatment Exclusion Criteria: * Having a treatable cause of seizure. * Having a progressive neurological or systemic disorder

Locations (47)

Outcomes

Primary Outcomes

Reduction in seizure frequency.

Time frame: 18 months

Secondary Outcomes

Seizure-free patients during each 3-month period

Time frame: 18 Months

Responder Rate 50% during each 3-month period (proportion of patients with 50% or greater reduction of seizures).

Time frame: 18 Months

Responder rate 75% during each 3-month period (proportion of patients with 75% or greater reduction of seizures).

Time frame: 18 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

Bruges, Belgium

Pfizer Investigational Site

Brussels, Belgium

Pfizer Investigational Site

Duffel, Belgium

Pfizer Investigational Site

Ghent, Belgium

Pfizer Investigational Site

Leuven, Belgium

Pfizer Investigational Site

Liège, Belgium

Pfizer Investigational Site

Tielt, Belgium

Pfizer Investigational Site

Yvoir, Belgium

Pfizer Investigational Site

Helsinki, Finland

Pfizer Investigational Site

Kuopio, Finland

...and 37 more locations